PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 0.29 ▲ 0.00 (0.05%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ContraFect Corporation | CFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.01394 | -4.59% | 0.289865 | 0.331 | 0.281 | 0.3251 | 0.3038 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.29 | 0.3636 | 0.0736 | 20.24% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 857 | 551,694 | $ 0.3138258 | $ 173,136 | 323,211 | 0.2693 - 2.6289 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:02:44 | formt | 983 | $ 0.29 | USD |
ContraFect Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 23.02M | 79.41M | $ -37.68M | -0.51 | 6.20 | 78.31M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 1.40% |
ContraFect News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/02/2019 | 17:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/02/2019 | 07:00 | GlobeNewswire Inc. | ContraFect Announces Plan for a Single Phase 3 Superiority.. |
| 10/01/2019 | 17:29 | GlobeNewswire Inc. | ContraFect to Host Development Update Call and Webcast on.. |
| 9/26/2019 | 07:00 | GlobeNewswire Inc. | ContraFect to Present New Exebacase Data Including a Late.. |
| 9/04/2019 | 17:07 | GlobeNewswire Inc. | ContraFect to Present at the 2019 Janney Healthcare.. |
| 8/28/2019 | 07:00 | GlobeNewswire Inc. | ContraFect Announces Presentation of New Data from its.. |
| 8/22/2019 | 16:20 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CFRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.39 | 0.4 | 0.281 | 0.3237 | 288k | -0.100135 | -25.68% |
| 1 Month | 0.39 | 0.47 | 0.281 | 0.3641 | 208k | -0.100135 | -25.68% |
| 3 Months | 0.462 | 0.5 | 0.2693 | 0.3711 | 265k | -0.172135 | -37.26% |
| 6 Months | 0.68 | 0.8 | 0.2693 | 0.4777 | 533k | -0.390135 | -57.37% |
| 1 Year | 1.77 | 2.6289 | 0.2693 | 0.6430 | 680k | -1.480135 | -83.62% |
| 3 Years | 2.4306 | 2.9266 | 0.2693 | 0.8956 | 302k | -2.140735 | -88.07% |
| 5 Years | 3.45 | 6.24 | 0.2693 | 1.2378 | 203k | -3.160135 | -91.60% |
ContraFect Description
| ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases. |
